Robert M. Wenham, MD, MS, FACS, FACOG
Chair and Director of Research, Department of Gynecologic Oncology
Senior Member, Chemical Biology and Molecular Medicine Program 
Moffitt Cancer Center  
Tampa, Florida 

Dr. Wenham is the Department Chair and Director of Research in Gynecologic Oncology at the Moffitt Cancer Center in Tampa, Florida. After undergraduate and graduate training in Biochemistry and Molecular Biology, he completed his Medical Doctorate at Southwestern Medical School in Dallas, Texas. He then completed an internship and residency at the Harvard Medical School integrated residency program (The Brigham and Women's Hospital/Massachusetts General Hospital) in Obstetrics and Gynecology in Boston, Massachusetts, and his fellowship in Gynecologic Oncology at Duke University in Durham, North Carolina. He currently is in the Department of Gynecologic Oncology at the Moffitt Cancer Center. His academic career consists of clinical gynecologic oncology; the training of fellows, residents, and medical students; research-related administrative and service roles; and clinical/translational research in oncology. He is a principal investigator (PI) on several consortia, industry, and investigator­-initiated trials. He has been the lead Pl for one of the largest prospective cancer tissue and data trials (TCCP) ever conducted, and that trial is setting the foundation for discovery in the epidemiology, detection, and treatment of malignancies. He also serves on national and international advisory boards and steering committees, as well as being an active member of several professional societies. 

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Robert W. Wenham MD, MS, FACOG, FACS—has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science. 

Authors/Presenters
Robert W. Wenham MD, MS, FACOG, FACS—has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science. 
Ursula Matulonis, MD—has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis; and receives financial or other material support from DSMB and Symphogen.
Angeles Alvarez Secord, MD—has disclosed that she receives grant/research support from AbbVie, Astra Zeneca, Clovis, Eisai, Immutep, Merck, OncoQuest, PharmaMar, Roche/Genentech, Seagen, Tesaro/GSK, VBL Therapeutics, and National Cancer Trial Network.
Shannon N. Westin, MD, MPH—has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, Eisai, Merck, Novartis, Pfizer, Roche/Genentech, Tesaro/GSK, and Zentalis; and receives grant/research support from AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, Mereo, Novartis, Roche/Genentech, and Tesaro/GSK.

Peer Reviewer
Justine Cooper Pickarski, MS, LGC—has no relevant financial relationships to disclose in relation to the content of this activity.